AGIOS PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Amortized Cost
AGIOS PHARMACEUTICALS, INC. (AGIO) had Debt Securities, Available-for-sale, Amortized Cost of $866.98 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $866.98M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $932.21M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $1.07B.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $1.16B.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $866.98M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $932.21M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $1.07B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.16B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.26B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $1.35B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.46B 10-K · filed 2026-02-12 |
| 2024-09-30 | $1.40B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $561.82M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $596.62M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $718.60M 10-K · filed 2025-02-13 |
| 2023-09-30 | $813.95M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $871.04M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $915.20M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $970.27M 10-K · filed 2024-02-15 |
| 2022-09-30 | $918.67M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.02B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.11B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $1.08B 10-K · filed 2023-02-23 |
| 2021-03-31 | $469.18M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $543.00M 10-K · filed 2022-02-24 |
| 2020-09-30 | $616.91M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $496.91M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $523.97M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $636.67M 10-K · filed 2021-02-25 |
| 2019-09-30 | $458.19M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $539.86M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $604.83M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $737.09M 10-K · filed 2020-02-19 |
| 2018-09-30 | $724.04M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $728.70M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $632.91M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $466.42M 10-Q · filed 2018-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |